vs
ANI PHARMACEUTICALS INC（ANIP）とJ&J SNACK FOODS CORP（JJSF）の財務データ比較。上の社名をクリックして会社を切り替えられます
J&J SNACK FOODS CORPの直近四半期売上が大きい（$343.8M vs $247.1M、ANI PHARMACEUTICALS INCの約1.4倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 0.3%、差は10.9%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs -5.2%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $17.0M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs -2.2%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
J&Jスナックフーズ社は米国の有名なブランドスナック菓子・冷凍飲料の製造・販売・流通業者で、本社はニュージャージー州マウントローレルに所在します。米国44州、メキシコ、カナダに175を超える生産・保管・流通拠点を構え、ナスダックグローバルセレクト市場に上場し、国内外の市場に事業を展開しています。
ANIP vs JJSF — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $343.8M |
| 純利益 | $27.5M | $883.0K |
| 粗利率 | — | 27.9% |
| 営業利益率 | 14.1% | 0.2% |
| 純利益率 | 11.1% | 0.3% |
| 売上前年比 | 29.6% | -5.2% |
| 純利益前年比 | 367.5% | -82.8% |
| EPS（希薄化後） | $1.14 | $0.05 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $343.8M | ||
| Q3 25 | $227.8M | $410.2M | ||
| Q2 25 | $211.4M | $454.3M | ||
| Q1 25 | $197.1M | $356.1M | ||
| Q4 24 | $190.6M | $362.6M | ||
| Q3 24 | $148.3M | $426.8M | ||
| Q2 24 | $138.0M | $440.0M | ||
| Q1 24 | $137.4M | $359.7M |
| Q4 25 | $27.5M | $883.0K | ||
| Q3 25 | $26.6M | $11.4M | ||
| Q2 25 | $8.5M | $44.2M | ||
| Q1 25 | $15.7M | $4.8M | ||
| Q4 24 | $-10.3M | $5.1M | ||
| Q3 24 | $-24.2M | $29.6M | ||
| Q2 24 | $-2.3M | $36.3M | ||
| Q1 24 | $18.2M | $13.3M |
| Q4 25 | — | 27.9% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 33.0% | ||
| Q1 25 | — | 26.9% | ||
| Q4 24 | — | 25.9% | ||
| Q3 24 | — | 31.8% | ||
| Q2 24 | — | 33.6% | ||
| Q1 24 | — | 30.1% |
| Q4 25 | 14.1% | 0.2% | ||
| Q3 25 | 15.9% | 2.8% | ||
| Q2 25 | 6.6% | 13.3% | ||
| Q1 25 | 13.3% | 1.7% | ||
| Q4 24 | -2.3% | 1.7% | ||
| Q3 24 | -13.8% | 9.3% | ||
| Q2 24 | 3.7% | 11.4% | ||
| Q1 24 | 14.8% | 5.0% |
| Q4 25 | 11.1% | 0.3% | ||
| Q3 25 | 11.7% | 2.8% | ||
| Q2 25 | 4.0% | 9.7% | ||
| Q1 25 | 8.0% | 1.4% | ||
| Q4 24 | -5.4% | 1.4% | ||
| Q3 24 | -16.3% | 6.9% | ||
| Q2 24 | -1.7% | 8.3% | ||
| Q1 24 | 13.2% | 3.7% |
| Q4 25 | $1.14 | $0.05 | ||
| Q3 25 | $1.13 | $0.59 | ||
| Q2 25 | $0.36 | $2.26 | ||
| Q1 25 | $0.69 | $0.25 | ||
| Q4 24 | $-0.45 | $0.26 | ||
| Q3 24 | $-1.27 | $1.52 | ||
| Q2 24 | $-0.14 | $1.87 | ||
| Q1 24 | $0.82 | $0.69 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $66.8M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $540.7M | $912.9M |
| 総資産 | $1.4B | $1.3B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $66.8M | ||
| Q3 25 | $262.6M | $105.9M | ||
| Q2 25 | $217.8M | $77.4M | ||
| Q1 25 | $149.8M | $48.5M | ||
| Q4 24 | $144.9M | $73.6M | ||
| Q3 24 | $145.0M | $73.4M | ||
| Q2 24 | $240.1M | $64.0M | ||
| Q1 24 | $228.6M | $43.6M |
| Q4 25 | $540.7M | $912.9M | ||
| Q3 25 | $505.8M | $966.7M | ||
| Q2 25 | $436.8M | $969.9M | ||
| Q1 25 | $418.6M | $935.0M | ||
| Q4 24 | $403.7M | $946.8M | ||
| Q3 24 | $405.9M | $957.0M | ||
| Q2 24 | $455.8M | $937.9M | ||
| Q1 24 | $452.0M | $915.7M |
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.4B | $1.4B | ||
| Q2 25 | $1.3B | $1.4B | ||
| Q1 25 | $1.3B | $1.4B | ||
| Q4 24 | $1.3B | $1.3B | ||
| Q3 24 | $1.3B | $1.4B | ||
| Q2 24 | $920.8M | $1.4B | ||
| Q1 24 | $914.5M | $1.3B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $36.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $17.0M |
| FCFマージンFCF / 売上 | 11.8% | 4.9% |
| 設備投資強度設備投資 / 売上 | 0.5% | 5.5% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 40.73× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $83.1M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $36.0M | ||
| Q3 25 | $44.1M | $66.4M | ||
| Q2 25 | $75.8M | $51.2M | ||
| Q1 25 | $35.0M | $12.3M | ||
| Q4 24 | $15.9M | $35.2M | ||
| Q3 24 | $12.5M | $46.3M | ||
| Q2 24 | $17.4M | $65.0M | ||
| Q1 24 | $18.3M | $12.7M |
| Q4 25 | $29.1M | $17.0M | ||
| Q3 25 | $38.0M | $44.8M | ||
| Q2 25 | $71.8M | $28.5M | ||
| Q1 25 | $32.5M | $-7.2M | ||
| Q4 24 | $13.5M | $16.1M | ||
| Q3 24 | $7.7M | $29.1M | ||
| Q2 24 | $13.0M | $45.3M | ||
| Q1 24 | $13.7M | $-4.0M |
| Q4 25 | 11.8% | 4.9% | ||
| Q3 25 | 16.7% | 10.9% | ||
| Q2 25 | 34.0% | 6.3% | ||
| Q1 25 | 16.5% | -2.0% | ||
| Q4 24 | 7.1% | 4.4% | ||
| Q3 24 | 5.2% | 6.8% | ||
| Q2 24 | 9.4% | 10.3% | ||
| Q1 24 | 10.0% | -1.1% |
| Q4 25 | 0.5% | 5.5% | ||
| Q3 25 | 2.7% | 5.3% | ||
| Q2 25 | 1.9% | 5.0% | ||
| Q1 25 | 1.3% | 5.5% | ||
| Q4 24 | 1.3% | 5.3% | ||
| Q3 24 | 3.2% | 4.0% | ||
| Q2 24 | 3.2% | 4.5% | ||
| Q1 24 | 3.3% | 4.6% |
| Q4 25 | 1.10× | 40.73× | ||
| Q3 25 | 1.66× | 5.84× | ||
| Q2 25 | 8.87× | 1.16× | ||
| Q1 25 | 2.23× | 2.55× | ||
| Q4 24 | — | 6.84× | ||
| Q3 24 | — | 1.56× | ||
| Q2 24 | — | 1.79× | ||
| Q1 24 | 1.00× | 0.96× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
JJSF
| Food Service | $219.2M | 64% |
| Frozen Beverages | $78.7M | 23% |
| Repair And Maintenance Service | $22.5M | 7% |
| Other | $12.7M | 4% |
| Machine Sales | $10.7M | 3% |
